{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:13:15Z","timestamp":1785597195977,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2024IP0105-1"],"award-info":[{"award-number":["2024IP0105-1"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15001-2","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:58:25Z","timestamp":1762775905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of intraductal carcinoma and invasive cribriform carcinoma as predictors of genetic mutations in systemic treatment-na\u00efve prostate cancer patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Sangmin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokyung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumjin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Kwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalsan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Gab","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hyuk","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungyo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"15001_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32074\/1591-951X-5-20","volume":"112","author":"E Szentirma","year":"2020","unstructured":"Szentirma E. Intraductal carcinoma of the prostate. Pathologica. 2020;112:17\u201324. https:\/\/doi.org\/10.32074\/1591-951X-5-20.","journal-title":"Pathologica"},{"key":"15001_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.euf.2020.10.007","volume":"7","author":"Y Zong","year":"2021","unstructured":"Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, et al. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. Eur Urol Focus. 2021;7:955\u201363. https:\/\/doi.org\/10.1016\/j.euf.2020.10.007.","journal-title":"Eur Urol Focus"},{"key":"15001_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0152","volume":"12","author":"MG Lawrence","year":"2020","unstructured":"Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, et al. Knowing what\u2019s growing: why ductal and intraductal prostate cancer matter. Sci Transl Med. 2020;12:eaaz0152. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0152.","journal-title":"Sci Transl Med"},{"key":"15001_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/JU.0000000000001290","volume":"204","author":"N Miura","year":"2020","unstructured":"Miura N, Mori K, Mostafaei H, Quhal F, Motlagh RS, Pradere B, et al. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J Urol. 2020;204:909\u201317. https:\/\/doi.org\/10.1097\/JU.0000000000001290.","journal-title":"J Urol"},{"key":"15001_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","volume":"45","author":"TH van der Kwast","year":"2021","unstructured":"van der Kwast TH, van Leenders GJ, Berney DM, Delahunt B, Evans AJ, Iczkowski KA, et al. Isup consensus definition of cribriform pattern prostate cancer. Am J Surg Pathol. 2021;45:1118. https:\/\/doi.org\/10.1097\/PAS.0000000000001728.","journal-title":"Am J Surg Pathol"},{"key":"15001_CR6","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","volume":"50","author":"D Trudel","year":"2014","unstructured":"Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer. 2014;50:1610\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2014.03.009.","journal-title":"Eur J Cancer"},{"key":"15001_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12916-022-02430-0","volume":"20","author":"S Zhu","year":"2022","unstructured":"Zhu S, Zhao J, Nie L, Yin W, Zhang Y, Zhao F, et al. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Med. 2022;20:237. https:\/\/doi.org\/10.1186\/s12916-022-02430-0.","journal-title":"BMC Med"},{"key":"15001_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pros.23484","volume":"78","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, et al. Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018;78:401\u20137. https:\/\/doi.org\/10.1002\/pros.23484.","journal-title":"Prostate"},{"key":"15001_CR9","doi-asserted-by":"publisher","unstructured":"Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, et al. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology. 2019;:1\u20139. https:\/\/doi.org\/10.1200\/PO.18.00327.","DOI":"10.1200\/PO.18.00327."},{"key":"15001_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","volume":"75","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75:378\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.009.","journal-title":"Eur Urol"},{"key":"15001_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 4.2024. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 10 Sep 2024."},{"key":"15001_CR12","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","volume":"38","author":"VN Giri","year":"2020","unstructured":"Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. JCO. 2020;38:2798\u2013811. https:\/\/doi.org\/10.1200\/JCO.20.00046.","journal-title":"JCO"},{"key":"15001_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"key":"15001_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102623","volume":"120","author":"GM Iannantuono","year":"2023","unstructured":"Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, et al. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023;120:102623. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102623.","journal-title":"Cancer Treat Rev"},{"key":"15001_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"key":"15001_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"key":"15001_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.euros.2022.11.011","volume":"49","author":"N Mehra","year":"2023","unstructured":"Mehra N, Kloots I, Vlaming M, Aluwini S, Dewulf E, Oprea-Lager DE, et al. Genetic aspects and molecular testing in prostate cancer: a report from a Dutch multidisciplinary consensus meeting. Eur Urol Open Sci. 2023;49:23\u201331. https:\/\/doi.org\/10.1016\/j.euros.2022.11.011.","journal-title":"Eur Urol Open Sci"},{"key":"15001_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.urology.2021.05.028","volume":"155","author":"AB Hesterberg","year":"2021","unstructured":"Hesterberg AB, Gordetsky JB, Hurley PJ. Cribriform prostate cancer: clinical pathologic and molecular considerations. Urology. 2021;155:47\u201354. https:\/\/doi.org\/10.1016\/j.urology.2021.05.028.","journal-title":"Urology"},{"issue":"2","key":"15001_CR19","doi-asserted-by":"publisher","DOI":"10.4258\/hir.2013.19.2.102","volume":"19","author":"S-Y Shin","year":"2013","unstructured":"Shin S-Y, Lyu Y, Shin Y, Choi HJ, Park J, Kim W-S, et al. Lessons learned from development of de-identification system for biomedical research in a Korean tertiary hospital. Healthc Inform Res. 2013;19(2):102. https:\/\/doi.org\/10.4258\/hir.2013.19.2.102.","journal-title":"Healthc Inform Res"},{"key":"15001_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part B: prostate and bladder tumours. Eur Urol. 2016;70:106\u201319. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028.","journal-title":"Eur Urol"},{"key":"15001_CR21","doi-asserted-by":"publisher","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u201399. https:\/\/doi.org\/10.1097\/PAS.0000000000001497","DOI":"10.1097\/PAS.0000000000001497"},{"key":"15001_CR22","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/pros.24352","volume":"82","author":"P Cresta Morgado","year":"2022","unstructured":"Cresta Morgado P, Mateo J. Clinical implications of homologous recombination repair mutations in prostate cancer. Prostate. 2022;82:S45. https:\/\/doi.org\/10.1002\/pros.24352.","journal-title":"Prostate"},{"key":"15001_CR23","doi-asserted-by":"crossref","unstructured":"Seabold S, Perktold J, Statsmodels. Econometric and Statistical Modeling with Python. Proceedings of the 9th Python in Science Conference. 2010;2010.","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"15001_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12885-017-3976-z","volume":"18","author":"R B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018;18:8. https:\/\/doi.org\/10.1186\/s12885-017-3976-z.","journal-title":"BMC Cancer"},{"key":"15001_CR25","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/PAS.0b013e3182a02169","volume":"37","author":"F Dong","year":"2013","unstructured":"Dong F, Yang P, Wang C, Wu S, Xiao Y, McDougal WS, et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol. 2013;37:1855. https:\/\/doi.org\/10.1097\/PAS.0b013e3182a02169.","journal-title":"Am J Surg Pathol"},{"key":"15001_CR26","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/his.14665","volume":"80","author":"JB Gordetsky","year":"2022","unstructured":"Gordetsky JB, Schaffer K, Hurley PJ. Current conundrums with cribriform prostate cancer. Histopathology. 2022;80:1038\u201340. https:\/\/doi.org\/10.1111\/his.14665.","journal-title":"Histopathology"},{"key":"15001_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JU.0000000000000526","volume":"203","author":"KJ Ericson","year":"2020","unstructured":"Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK. Diagnostic accuracy of prostate biopsy for detecting cribriform Gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J Urol. 2020;203:311\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000000526.","journal-title":"J Urol"},{"key":"15001_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/his.13747","volume":"74","author":"M Masoomian","year":"2019","unstructured":"Masoomian M, Downes MR, Sweet J, Cheung C, Evans AJ, Fleshner N, et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology. 2019;74:474\u201382. https:\/\/doi.org\/10.1111\/his.13747.","journal-title":"Histopathology"},{"key":"15001_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41391-024-00910-3","volume":"28","author":"RM Bernardino","year":"2025","unstructured":"Bernardino RM, Yin LB, Lajkosz K, Cockburn JG, Wettstein M, Sayyid RK, et al. Undetected cribriform and intraductal prostate cancer at biopsy is associated with adverse outcomes. Prostate Cancer Prostatic Dis. 2025;28:187\u201392. https:\/\/doi.org\/10.1038\/s41391-024-00910-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"15001_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","volume":"147","author":"R Lozano","year":"2021","unstructured":"Lozano R, Salles DC, Sandhu S, Arag\u00f3n IM, Thorne H, L\u00f3pez-Campos F, et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur J Cancer. 2021;147:74\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.027.","journal-title":"Eur J Cancer"},{"key":"15001_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.humpath.2024.01.005","volume":"144","author":"J Mahlow","year":"2024","unstructured":"Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, et al. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Hum Pathol. 2024;144:28\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2024.01.005.","journal-title":"Hum Pathol"},{"key":"15001_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00764-1","author":"IM Shui","year":"2023","unstructured":"Shui IM, Burcu M, Shao C, Chen C, Liao C-Y, Jiang S, et al. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00764-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"15001_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1162644","volume":"13","author":"N Lukashchuk","year":"2023","unstructured":"Lukashchuk N, Barnicle A, Adelman CA, Armenia J, Kang J, Barrett JC, et al. Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Front Oncol. 2023;13:1162644. https:\/\/doi.org\/10.3389\/fonc.2023.1162644.","journal-title":"Front Oncol"},{"issue":"4_suppl","key":"15001_CR34","doi-asserted-by":"publisher","first-page":"TPS353","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS353","volume":"42","author":"RR McKay","year":"2024","unstructured":"McKay RR, Liu L, Pu M, Araneta A, Wang L, Castano N, et al. A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1\/2 gene alterations (NePtune). JCO. 2024;42(4_suppl):TPS353\u2013TPS353. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.TPS353.","journal-title":"JCO"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15001-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:12:03Z","timestamp":1762884723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15001-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15001"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15001-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (IRB No. 2024\u2009\u2212\u20090991). All participants provided written informed consent for genetic testing and use of clinical data. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1736"}}